Skip to main content

Featured

Ontario’s Math Struggles Spark Provincial Review of Student Testing

Ontario’s latest standardized test results reveal that math achievement remains a serious concern across the province , with many students failing to meet expected benchmarks. The Education Quality and Accountability Office (EQAO) released its 2024–2025 assessment data this week, showing that only 51% of Grade 6 students and 58% of Grade 9 students met the provincial math standard , while Grade 3 students fared slightly better at 64%. Despite modest improvements compared to previous years, the results underscore a persistent gap in student performance. Education Minister Paul Calandra acknowledged that progress has been too slow, announcing the creation of a two-member advisory body to review Ontario’s approach to standardized testing and curriculum delivery . The review will examine whether current teaching strategies, resources, and assessment methods are effectively supporting student learning. The EQAO results also highlighted disparities among student groups and school boards ,...
Post a Comment
Read more

article

Labels

Alzheimer’s Drug Donanemab Receives FDA Advisers’ Endorsement for Slowing Disease Progression

 

A significant milestone has been reached in the fight against Alzheimer’s disease. Eli Lilly’s closely watched Alzheimer’s drug, donanemab, has won the unanimous backing of federal health advisers. The drug is specifically intended for people with mild dementia caused by this brain-robbing disease.

The decision by the Food and Drug Administration (FDA) advisers comes after careful consideration of the drug’s benefits and risks. Donanemab has demonstrated the ability to modestly slow cognitive decline and memory problems associated with Alzheimer’s. Although it’s not a cure, this endorsement represents a promising step forward in managing the disease.

Here are the key points:

  1. Effectiveness: Donanemab has shown effectiveness in slowing cognitive decline. Patients who received monthly intravenous infusions of the drug declined about 35% more slowly than those who received a placebo.
  2. Risk Assessment: The FDA panel weighed the risks, including side effects like brain swelling and bleeding, which will need monitoring. Despite these risks, the panel concluded that the drug’s benefits outweighed them.
  3. Tau Protein Screening: Unlike previous concerns about tau protein screening, most panelists believed there was enough evidence to prescribe the drug broadly without requiring such screening.
  4. FDA Decision: The FDA will make the final decision on approval later this year. If approved, donanemab would become only the second Alzheimer’s drug in the U.S. shown to convincingly slow cognitive decline.

This endorsement brings hope to individuals and families affected by Alzheimer’s, and we eagerly await the FDA’s final decision. Stay tuned for further updates on this groundbreaking development! 

Labels:

Comments

Post a Comment